FDA Approves Zongertinib for HER2-Mutated Lung Cancer

The FDA has approved zongertinib (Hernexeos) under accelerated approval for treating adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 tyrosine kinase domain activating mutations. This represents a significant advancement in precision oncology for lung cancer patients.

HER2 mutations occur in approximately 2-4% of NSCLC cases, creating a distinct molecular subtype that requires targeted treatment approaches. Unlike HER2 amplification seen in breast cancer, these are activating mutations in the tyrosine kinase domain that drive tumor growth through different mechanisms.

The accelerated approval pathway allows earlier patient access to promising therapies based on preliminary evidence, though confirmatory trials will be required to verify clinical benefit. This approval follows sevabertinib (Hyrnuo), which received similar approval in November 2025 for the same indication, indicating rapid progress in this therapeutic area.

For patients and clinicians, this approval expands treatment options for a previously difficult-to-treat subset of lung cancer. Genetic testing for HER2 mutations will become increasingly important in treatment planning, as these targeted therapies offer more precise approaches than traditional chemotherapy. The availability of multiple HER2-targeted options may also provide alternatives if resistance develops to first-line therapy, potentially improving long-term outcomes for this patient population.